Alpha synuclein PET imaging, a step closer to in vivo neuropathology in Parkinson’s disease and related disorders

In this issue of Neuron, Endo et al. 1 Endo H. Ono M. Takado Y. Matsuoka K. Takahashi M. Tagai K. Kataoka Y. Hirata K. Takahata K. Seki C. et al. Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseases. Neuron. 2024; 112: 2540-2557.e8https://doi.org/10.1016/j.neuron.2024.05.006 Abstract Full Text Full Text PDF Scopus (1) Google Scholar develop a PET tracer capable of detecting alpha-synuclein (ɑ-syn). With validation in animal models and humans, this tracer brings us closer to being able to monitor the synuclein aggregation process and associated pathological changes in Parkinson's disease (PD) and other synucleinopathies. In this issue of Neuron, Endo et al. 1 Endo H. Ono M. Takado Y. Matsuoka K. Takahashi M. Tagai K. Kataoka Y. Hirata K. Takahata K. Seki C. et al. Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseases. Neuron. 2024; 112: 2540-2557.e8https://doi.org/10.1016/j.neuron.2024.05.006 Abstract Full Text Full Text PDF Scopus (1) Google Scholar develop a PET tracer capable of detecting alpha-synuclein (ɑ-syn). With validation in animal models and humans, this tracer brings us closer to being able to monitor the synuclein aggregation process and associated pathological changes in Parkinson's disease (PD) and other synucleinopathies. Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseasesEndo et al.NeuronJune 5, 2024